These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 29804556)
21. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer. Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751 [TBL] [Abstract][Full Text] [Related]
22. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells. Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334 [TBL] [Abstract][Full Text] [Related]
23. An in vitro model for the development of acquired tamoxifen resistance. Guney Eskiler G; Cecener G; Tunca B; Egeli U Cell Biol Toxicol; 2016 Dec; 32(6):563-581. PubMed ID: 27585693 [TBL] [Abstract][Full Text] [Related]
24. Dexamethasone-tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells. Gaballah AI; Elsherbiny AA; Sharaky M; Hamed NO; Raslan NA; Almilaibary A; Fayyad RMA; Ousman MS; Hamdan AME; Fahim SA Biosci Rep; 2024 Jul; 44(7):. PubMed ID: 38864530 [TBL] [Abstract][Full Text] [Related]
25. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365 [TBL] [Abstract][Full Text] [Related]
26. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519 [TBL] [Abstract][Full Text] [Related]
27. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103 [TBL] [Abstract][Full Text] [Related]
28. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235 [TBL] [Abstract][Full Text] [Related]
29. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709 [TBL] [Abstract][Full Text] [Related]
30. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells. Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors. Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426 [TBL] [Abstract][Full Text] [Related]
32. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Wang L; Zhang X; Wang ZY Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147 [TBL] [Abstract][Full Text] [Related]
33. A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor α target genes. Bonneville R; Jin VX Bioinformatics; 2013 Jan; 29(1):22-8. PubMed ID: 23104890 [TBL] [Abstract][Full Text] [Related]
34. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression. Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288 [TBL] [Abstract][Full Text] [Related]
35. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression. Zhang B; Zhang X; Tang B; Zheng P; Zhang Y Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650 [TBL] [Abstract][Full Text] [Related]
36. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer. Xie Y; Han X; Yu J; Yuan M; Yan Y; Qin J; Lan L; Wang Y J Cancer Res Clin Oncol; 2023 Dec; 149(20):18103-18117. PubMed ID: 37999751 [TBL] [Abstract][Full Text] [Related]
37. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173 [TBL] [Abstract][Full Text] [Related]
38. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer. Madhavan S; Gusev Y; Singh S; Riggins RB J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350 [TBL] [Abstract][Full Text] [Related]
39. Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer. Fu H; Han X; Guo W; Zhao X; Yu C; Zhao W; Feng S; Wang J; Zhang Z; Lei K; Li M; Wang T Sci Rep; 2024 Oct; 14(1):22988. PubMed ID: 39362925 [TBL] [Abstract][Full Text] [Related]
40. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Raha P; Thomas S; Thurn KT; Park J; Munster PN Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]